Why UnitedHealth Stock Is Sinking Today
UnitedHealth Group's stock declined following its Q2 earnings report, which revealed a significant miss on earnings per share and a lower-than-expected full-year outlook.
The company attributed its disappointing guidance to rising medical costs and changes in its business plans.
Beyond financial performance, UnitedHealth is facing multiple challenges, including a CEO resignation, two DOJ investigations into Medicare billing, and allegations of unethical practices related to nursing home payments.
10 stocks we like better than UnitedHealth Group ›
Shares of UnitedHealth Group (NYSE: UNH) are falling on Tuesday, down 5.4% as of 2:20 p.m. ET. The drop comes as the S&P 500 (SNPINDEX: ^GSPC) declined 0.3% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) fell 0.2%.
The troubled health insurance giant set worse-than-expected guidance on Tuesday.
UnitedHealth continues to struggle
The company reported its Q2 financials today, revealing the insurer is still very much struggling. The company was able to deliver on revenue, reporting $111.62 billion versus the expected $111.52 billion, but it missed significantly on earnings per share (EPS), reporting $4.08 per share when Wall Street expected $4.48 per share.
More concerning was the company's outlook for the full year. UnitedHealth expects EPS of at least $16 and sales of $445.5 billion to $448 billion. Wall Street's expectations were EPS of at $20.9 and sales of $449.2.
The company cited rising medical costs and abandoned "previously planned portfolio actions" as reasons for the disappointing outlook.
UnitedHealth's problems mount
This latest disappointing quarter is the latest in a series of bad news related to the massive insurer: The company's CEO abruptly stepped down, citing "personal reasons"; it was revealed that the DOJ currently has two investigations into the company's Medicare billing practices; and an exposé published by the Guardian alleges the company was paying nursing homes to keep residents out of the hospital when they needed elevated levels of care.
https://www.theguardian.com/us-news/2025/may/21/unitedhealth-nursing-homes-payments-hospital-transfers
There are just too many issues facing UnitedHealth at the moment, with no clear picture of an imminent turnaround. I would stay away from the stock.
Should you buy stock in UnitedHealth Group right now?
Before you buy stock in UnitedHealth Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and UnitedHealth Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!*
Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 29, 2025
Johnny Rice has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.
Why UnitedHealth Stock Is Sinking Today was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
DSM-Firmenich First Half 2025 Earnings: EPS: €1.94 (vs €0.16 in 1H 2024)
DSM-Firmenich (AMS:DSFIR) First Half 2025 Results Key Financial Results Revenue: €6.51b (up 3.4% from 1H 2024). Net income: €510.0m (up by €468.0m from 1H 2024). Profit margin: 7.8% (up from 0.7% in 1H 2024). The increase in margin was primarily driven by lower expenses. EPS: €1.94 (up from €0.16 in 1H 2024). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period DSM-Firmenich Earnings Insights Looking ahead, revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Chemicals industry in Europe. Performance of the market in the Netherlands. The company's shares are down 7.8% from a week ago. Risk Analysis It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with DSM-Firmenich, and understanding this should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
58-Year-Old Lottery Winner Tried To Strike A Deal With Teen Son, But Backed Out When The 19-Year-Old Wanted 80% —'I Didn't Realize How Greedy He Was'
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. We all daydream about winning the lottery. Maybe it's a beach house. Maybe it's early retirement. Or maybe—if you're a parent—you imagine setting your kid up for life. That's exactly what a 58-year-old father tried to do when he hit the jackpot with a $1,000-a-day-for-life prize. But instead of gratitude, he got a negotiation that made him rethink everything. In a viral Reddit post, the dad explained how he approached his 19-year-old son with a plan: he'd hand over the winning ticket, and in return, the son would give him half the money until the father passed. After that, the son would receive 100% of the daily payout for the rest of his life. Related: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.30/share. Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Here's how you can earn passive income with just $10. Although he didn't spell out all the logic, the intent seemed clear: his son, being 19, had a much longer life expectancy and could benefit from the "for life" prize far longer than he could. The father was essentially trying to gift his son a lifetime of financial security—while covering himself with a fair 50/50 arrangement in the meantime. The teen's response? Not exactly a warm embrace. "He came back and said it wasn't really fair for me to want half," the dad wrote. "He said that I could live another 40 years. That he might need the money more and that I should take 20%." So the dad thought about it—and then signed the ticket and claimed the lump sum himself. He's now working with a lawyer to set his son up in other ways: college will be covered, a house fund will be waiting, and a trust is being arranged to ensure long-term support. Still, the son is angry—and so is the dad's ex, who apparently expected a cut too. Reddit, of course, had thoughts. A lot of them. "Dad is a sweetheart, son a greedy pig," one user wrote. Another called it "rage bait," adding, "No way is someone that greedy and s*****." One of the top-rated replies summed it up like this: "A 19-year-old kid tried to negotiate from $180K/year for doing nothing to $290K/year with zero leverage and was surprised when it blew up in his face." Some were quick to defend the father's pivot to the lump sum. "It was probably for the best," a commenter wrote. "Judging the son's character... the father was probably going to get hosed on that deal pretty much immediately." Others pointed out just how generous the original offer was. "If my father had offered me that deal, I would show up at his doorstep every morning with his cash, a dozen doughnuts, and his coffee exactly the way he likes it." For what it's worth, the dad isn't leaving his son high and dry—but he's not pretending the whole thing didn't sting. "I thought I was being smart, but I didn't realize how greedy he was," he wrote. In cases like this—where family, money, and long-term plans collide—it's often smart to bring in a professional. Even if you're not lucky enough to win the lottery, platforms like SmartAsset can connect you with financial advisors who help with everything from retirement planning to tax strategy to making sure your kids don't end up arguing over the inheritance. Whether you're setting up support for your kids, planning your estate, or just trying to avoid a financial decision you'll regret later, good advice can go a long way. Because giving your kid the golden goose? That's one thing. Watching him complain it's not laying fast enough—that's something else entirely. See Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. It's no wonder Jeff Bezos holds over $250 million in art — this beloved alternative asset has outpaced the S&P 500 since 1995, delivering an average annual return of 11.4%. This article 58-Year-Old Lottery Winner Tried To Strike A Deal With Teen Son, But Backed Out When The 19-Year-Old Wanted 80% —'I Didn't Realize How Greedy He Was' originally appeared on Sign in to access your portfolio
Yahoo
11 minutes ago
- Yahoo
Results: Siemens Healthineers AG Beat Earnings Expectations And Analysts Now Have New Forecasts
A week ago, Siemens Healthineers AG (ETR:SHL) came out with a strong set of quarterly numbers that could potentially lead to a re-rate of the stock. It was overall a positive result, with revenues beating expectations by 2.0% to hit €5.7b. Siemens Healthineers reported statutory earnings per share (EPS) €0.49, which was a notable 17% above what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. After the latest results, the 18 analysts covering Siemens Healthineers are now predicting revenues of €24.6b in 2026. If met, this would reflect a modest 5.4% improvement in revenue compared to the last 12 months. Per-share earnings are expected to climb 17% to €2.29. In the lead-up to this report, the analysts had been modelling revenues of €24.8b and earnings per share (EPS) of €2.34 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a small dip in their earnings per share forecasts. See our latest analysis for Siemens Healthineers The consensus price target held steady at €59.86, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. There are some variant perceptions on Siemens Healthineers, with the most bullish analyst valuing it at €65.00 and the most bearish at €50.00 per share. This is a very narrow spread of estimates, implying either that Siemens Healthineers is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions. These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Siemens Healthineers' past performance and to peers in the same industry. It's pretty clear that there is an expectation that Siemens Healthineers' revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 4.3% growth on an annualised basis. This is compared to a historical growth rate of 9.0% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 5.6% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Siemens Healthineers. The Bottom Line The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Siemens Healthineers. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates. Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Siemens Healthineers going out to 2027, and you can see them free on our platform here. And what about risks? Every company has them, and we've spotted 1 warning sign for Siemens Healthineers you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
